AFT Pharmaceuticals says first-half loss widened to $8.4M, cash burn continues

Jonathan Underhill
Thu, 10 Nov 2016

By Jonathan Underhill Nov. 11 (BusinessDesk) - AFT Pharmaceuticals, the maker of ibuprofen-paracetamol painkiller Maxigesic, said its operating loss widened in the first half as it continues with its global rollout and trials new versions of its products. The operating loss was about $8.4 million in the six months ended Sept. 30, from a loss of $3.5 million a year earlier, the Auckland-based company said in a statement. Revenue rose 1 percent to $29.8 million. At the company's annual meeting in August, it said it was on track to break...
BRIAN GAYNOR: Aluminium smelter reaches use by date
Brian Gaynor | Sat, 11 Jul 2020

The negative market reaction to Rio Tinto’s announcement that it was winding down the Tiwai Point aluminium smelter was overdone, particularly for investors with long-term perspectives. The smelter...

MARKET CLOSE: NZ shares fall as energy sector sell-off continues
Dan Brunskill | Fri, 10 Jul 2020

New Zealand shares fell as energy stocks declined for a second day following the announcement Rio Tinto’s New Zealand aluminium smelter will close. Chorus led the market lower on the risk of more r...

Metlifecare and EQT enter new $6 per share takeover agreement
Jenny Ruth | Fri, 10 Jul 2020

Metlifecare said it has entered into a new scheme of arrangement with Swedish company EQT to buy all its shares for $6 each, a dollar less than the earlier deal EQT had repudiated, but only four of th...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.

Sponsored: What’s next for the future of the office?

Think everyone is going to keep working from home? No so fast, says Milford Asset Management.